Immix Biopharma IncNASDAQ:IMMX
- LAST PRICE1.5900
- TODAY'S CHANGE (%)-0.0300 (-1.8519%)
- Bid / Lots1.5000/ 5
- Ask / Lots1.6300/ 40
- Open / Previous Close1.6100 / 1.6200
- Day Range
- 52 Week Range
- Volume57,116
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMMX |
|---|---|---|
| 09:32 ET | 229 | 1.61 |
| 09:42 ET | 100 | 1.62 |
| 09:46 ET | 100 | 1.63 |
| 09:48 ET | 200 | 1.62 |
| 09:50 ET | 100 | 1.62 |
| 09:53 ET | 100 | 1.62 |
| 09:55 ET | 430 | 1.59 |
| 10:00 ET | 100 | 1.62 |
| 10:02 ET | 100 | 1.62 |
| 10:04 ET | 284 | 1.61 |
| 10:06 ET | 100 | 1.61 |
| 10:08 ET | 100 | 1.61 |
| 10:09 ET | 652 | 1.61 |
| 10:13 ET | 100 | 1.61 |
| 10:15 ET | 295 | 1.61 |
| 10:20 ET | 100 | 1.61 |
| 10:24 ET | 100 | 1.62 |
| 10:27 ET | 100 | 1.62 |
| 10:29 ET | 100 | 1.62 |
| 10:33 ET | 100 | 1.62 |
| 10:38 ET | 100 | 1.61 |
| 10:40 ET | 200 | 1.61 |
| 10:42 ET | 100 | 1.61 |
| 10:45 ET | 700 | 1.6099 |
| 10:47 ET | 100 | 1.62 |
| 10:51 ET | 100 | 1.62 |
| 10:54 ET | 100 | 1.62 |
| 10:56 ET | 100 | 1.62 |
| 11:00 ET | 100 | 1.62 |
| 11:02 ET | 1720 | 1.62 |
| 11:03 ET | 1600 | 1.62 |
| 11:07 ET | 100 | 1.62 |
| 11:14 ET | 100 | 1.62 |
| 11:18 ET | 200 | 1.62 |
| 11:21 ET | 100 | 1.63 |
| 11:25 ET | 100 | 1.63 |
| 11:30 ET | 100 | 1.64 |
| 11:36 ET | 100 | 1.64 |
| 11:39 ET | 100 | 1.64 |
| 11:50 ET | 100 | 1.63 |
| 11:52 ET | 100 | 1.63 |
| 11:54 ET | 200 | 1.62 |
| 12:03 ET | 100 | 1.62 |
| 12:10 ET | 100 | 1.62 |
| 12:12 ET | 100 | 1.62 |
| 12:15 ET | 100 | 1.62 |
| 12:17 ET | 100 | 1.62 |
| 12:21 ET | 100 | 1.62 |
| 12:24 ET | 300 | 1.61 |
| 12:28 ET | 100 | 1.61 |
| 12:30 ET | 1100 | 1.61 |
| 12:32 ET | 152 | 1.5982 |
| 12:33 ET | 200 | 1.61 |
| 12:37 ET | 200 | 1.59 |
| 12:39 ET | 100 | 1.61 |
| 12:44 ET | 100 | 1.61 |
| 12:46 ET | 300 | 1.59 |
| 12:53 ET | 100 | 1.6 |
| 12:55 ET | 3233 | 1.5878 |
| 12:57 ET | 178 | 1.59 |
| 01:02 ET | 100 | 1.59 |
| 01:04 ET | 100 | 1.59 |
| 01:06 ET | 1268 | 1.5869 |
| 01:08 ET | 100 | 1.585 |
| 01:09 ET | 100 | 1.585 |
| 01:11 ET | 600 | 1.58 |
| 01:15 ET | 100 | 1.57 |
| 01:20 ET | 100 | 1.56 |
| 01:26 ET | 100 | 1.57 |
| 01:27 ET | 900 | 1.57 |
| 01:31 ET | 100 | 1.56 |
| 01:36 ET | 100 | 1.56 |
| 01:38 ET | 300 | 1.56 |
| 01:42 ET | 100 | 1.56 |
| 01:44 ET | 500 | 1.57 |
| 01:47 ET | 100 | 1.57 |
| 01:49 ET | 100 | 1.57 |
| 01:54 ET | 100 | 1.57 |
| 01:56 ET | 190 | 1.5597 |
| 01:58 ET | 100 | 1.57 |
| 02:00 ET | 100 | 1.57 |
| 02:03 ET | 100 | 1.57 |
| 02:05 ET | 100 | 1.57 |
| 02:07 ET | 100 | 1.57 |
| 02:09 ET | 100 | 1.57 |
| 02:14 ET | 500 | 1.5693 |
| 02:18 ET | 100 | 1.575 |
| 02:20 ET | 5200 | 1.57 |
| 02:23 ET | 100 | 1.5797 |
| 02:25 ET | 100 | 1.58 |
| 02:30 ET | 100 | 1.58 |
| 02:32 ET | 100 | 1.59 |
| 02:34 ET | 100 | 1.59 |
| 02:38 ET | 100 | 1.59 |
| 02:39 ET | 100 | 1.59 |
| 02:43 ET | 100 | 1.59 |
| 03:15 ET | 100 | 1.6 |
| 03:17 ET | 100 | 1.6 |
| 03:19 ET | 100 | 1.6 |
| 03:24 ET | 320 | 1.6 |
| 03:26 ET | 100 | 1.6 |
| 03:28 ET | 100 | 1.6 |
| 03:30 ET | 200 | 1.59 |
| 03:32 ET | 100 | 1.6 |
| 03:33 ET | 100 | 1.6 |
| 03:35 ET | 400 | 1.6 |
| 03:37 ET | 100 | 1.6 |
| 03:39 ET | 100 | 1.6 |
| 03:42 ET | 100 | 1.6 |
| 03:44 ET | 2463 | 1.595 |
| 03:46 ET | 4691 | 1.58 |
| 03:50 ET | 100 | 1.58 |
| 03:51 ET | 762 | 1.59 |
| 03:53 ET | 1000 | 1.59 |
| 03:55 ET | 900 | 1.59 |
| 03:57 ET | 1700 | 1.6 |
| 04:00 ET | 4740 | 1.59 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Immix Biopharma Inc | 43.6M | -1.9x | --- |
Intensity Therapeutics Inc | 43.4M | -2.9x | --- |
OS Therapies Inc | 44.1M | -7.3x | --- |
Achilles Therapeutics PLC | 43.1M | -0.7x | --- |
CalciMedica Inc | 44.9M | -2.1x | --- |
CERo Therapeutics Holdings Inc | 42.1M | -0.8x | --- |
Company Information
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Contact Information
- Headquarters
- 11400 West Olympic Blvd., Suite 200LOS ANGELES, CA, United States 90064
- Phone
- 310-651-8041
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Ilya Rachman
- Scientific Co-Founder
- Vladimir Torchilin
- Chief Financial Officer, Director
- Gabriel Morris
- Head - Chemistry, Manufacturing, and Control
- Nandan Oza
- Acting Chief Medical Officer, Head - Clinical Development
- Graham Ross
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $43.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 27.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.84 |
Book Value | $0.82 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
